
|Articles|July 1, 2004
- Psychiatric Times Vol 21 No 8
- Volume 21
- Issue 8
Compulsive
Another day without timeto write: patients call in crisis,apple trees need stakes,cord wood waits to be stacked,
Advertisement
Another day without time
to write: patients call in crisis,
apple trees need stakes,
cord wood waits to be stacked,
and rows of pink-topped turnips
remain buried in half-frozen earth.
I rush from chore to chore,
the smell of snow in the air,
scolding myself, "Chop wood,
carry water!" but only feel anxious
as an intern with a pager
that will call code blue.
Overhead, swans fly south,
no doubt where they're headed.
Articles in this issue
about 22 years ago
Budget Cuts Continue to Threaten State Medicaid Programsabout 22 years ago
Treating Eating Disorders: the Pitfalls and Perplexitiesover 22 years ago
New Knowledge and New Conceptionsover 22 years ago
Psychodynamic Psychotherapy for Personality Disordersover 22 years ago
Borderline Personality Disorder: An Overviewover 22 years ago
DHEA Lessens Depressive Symptoms, NIMH Study Showsover 22 years ago
Borderline Personality Disorder: An OverviewAdvertisement
Related to this article

Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.

Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.

Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.

How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.

Male athletes with anorexia often go unnoticed as “discipline”; learn red flags, sport-specific risks, health consequences, and treatment steps for earlier diagnosis.

Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.

Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
Advertisement
Advertisement
Trending on Psychiatric Times
1
How Best to Manage Treatment-Resistant Depression
2
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
3
Can Durable Response to Psilocybin Reshape Treatment-Resistant Depression Care?
4
Podcast: Using Antipsychotic Plasma Levels to Guide Schizophrenia Treatment With Jonathan M. Meyer, MD
5

